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We investigated whether maternal breast cancer affects birth outcome in a nationwide cohort study of 695 births from 1973 to 2002
of women with breast cancer with respect to preterm birth, low birth weight at term, stillbirth and congenital abnormalities as well as
mean birth weight, compared with the outcomes of 33443 births from unaffected mothers. There was no excess risk of adverse birth
outcome for the 216 newborns of women with breast cancer before pregnancy. Stratification by mother’s treatment did not change
the results. For 37 newborns of women diagnosed during pregnancy, the prevalence ratio (PR) of preterm birth was 8.1 (95%
confidence interval (CI): 3.8–17). However, 10 of the 12 preterm deliveries among these women were elective early deliveries.
Among 442 births of women diagnosed in the 2 years from time of delivery, the PR of preterm birth was 1.4 (95% CI: 1.0–2.0), and
the PR of low birth weight at term for boys was 2.9 (95% CI: 1.3–6.3). Overall, our results are reassuring regarding the risks of
adverse birth outcome for breast cancer patients.
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In western countries many women postpone childbearing for
personal or professional reasons (Dow et al, 1994), which both
increases their risk for breast cancer (Kelsey et al, 1993) and
reduces the period between giving birth and breast cancer
diagnosis. In the future, therefore, more breast cancer patients
will have recently given birth, been pregnant concurrent with their
diagnosis, or not yet started their childbearing at the time of their
diagnosis.
Biological mechanisms related to the cancer or its treatment
may impact foetal growth, development, and teratogenesis
(Zemlickis et al, 1992; Zhu et al, 2002). However, the epidemiologic
evidence of the effect of breast cancer on birth outcome is limited.
The few studies of women who were diagnosed with breast cancer
before pregnancy have focused on maternal prognosis (Ribeiro
et al, 1986; Sutton et al, 1990; Dow et al, 1994; Malamos et al, 1996;
Kroman et al, 1997; Velentgas et al, 1999; Blakely et al, 2003).
Thus, no population-based cohort study of birth outcome in
women diagnosed with breast cancer before pregnancy has been
published. Cohorts without control groups including between four
and 121 women (Ribeiro et al, 1986; Daly and Donnellan, 1992;
Berry et al, 1999; Giacalone et al, 1999; Kuerer et al, 2002; Ring
et al, 2005) have shown that the majority of women who are
diagnosed with breast cancer during or shortly after pregnancy
give birth to healthy children. Two controlled studies, however,
suggested an increased risk of preterm birth and low birth weight
for offspring of these women (Zemlickis et al, 1992; Smith et al,
2001). Therefore, within a cohort study, we examined birth
outcome in all women diagnosed with breast cancer in Denmark
from 1943 to 2002, compared with women without cancer.
MATERIAL AND METHODS
Study population
We conducted this nationwide cohort study based on all Danish
women who were diagnosed with breast cancer from January 1,
1943 through December 31, 2002, and who gave birth from January
1, 1973 through December 31, 2002. Women were included if they
were diagnosed at any time before pregnancy, during the
pregnancy, or until 2 years post partum. Their birth outcome
was compared with the outcome in a comparison cohort selected
from other births in Denmark. We restricted all analyses to
singleton births only, and each pregnancy was included in the
analyses as an independent event.
Breast cancer cohort Women with breast cancer were identified
from the Danish Cancer Registry, which has kept records of all
incident cases of cancer in Denmark since 1943, classified
according to the International Classification of Diseases (ICD-7)
(Storm et al, 1997). The records include the civil registration
number, diagnosis, date of diagnosis, method of verification,
extent of spread of the tumour at time of diagnosis, and treatment
given within 4 months after diagnosis. We identified all women
with a diagnosis of breast cancer (ICD-7 codes 170.0–170.5). We
excluded all cases of ‘Carcinoma in situ’ and six cases of sarcoma
involving the breast. Women with breast cancer were linked to the
Danish Medical Birth Registry with data on all births in Denmark
since January 1, 1973 (Kristensen et al, 1996) obtained from birth
notifications, filled in by midwives (in Denmark all births,
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yincluding home births, are attended by midwives). The main
variables are the civil registration number of the mother and child,
date and place of birth, gestational age, birth weight, and parity.
Birth weights X7000g probably reflected coding errors and
were excluded from the analyses. Likewise, we excluded births
registered without a gestational age or when this was less than
20 weeks or more than 44 weeks. Owing to a change in
classification procedures in the Birth Registry in 1978, there was
more missing data on gestational age for the years 1978–1981 than
for other years (mean missing proportion, 21.7% for 1978–1981,
compared with 2.4% for the years 1973–1977, and 0.7% for the
years 1982–2002). We identified 695 singleton births delivered by
women in the breast cancer cohort.
Comparison cohort For each birth by a woman with breast
cancer, 50 comparison births matched by month and year of birth,
by county of mother’s residence, and born to 50 different women,
who were not diagnosed with any cancer before or during
the pregnancy or until 2 years after the birth were selected from
the Birth Registry. If fewer than 50 comparison births fulfilled the
criteria, we used the available number of births. If more than 50
comparison births were eligible after matching, the subset of 50
was randomly selected. On average, 48 comparison births were
selected for each exposed birth. Altogether, 33443 single births
were selected for the comparison cohort.
Outcome data The data collected from the Birth Registry
included preterm birth (birth before 37 completed weeks of
pregnancy), low birth weight at term (birth weight o2500g with
a gestational age X37 completed weeks of pregnancy), stillbirth
(delivery of a dead foetus at 28 completed weeks of gestation
or later in pregnancy), male proportion of newborns, and birth
weight. Data on potential confounders included maternal age,
parity, gestational age, and calendar period of the birth. Data about
congenital abnormalities (including chromosomal abnormalities)
diagnosed during the first year after the birth were collected
from the Danish Hospital Discharge Registry, established in 1977,
with records of all discharges from Danish hospitals. The recorded
information includes the civil registration number, dates of
admission and discharge, and up to 20 discharge diagnoses, using
the International Classification of Diseases (ICD-8 before 1994 and
ICD-10 from 1994 onward (Andersen et al, 1999)). The codes for
congenital abnormalities (including chromosomal abnormalities)
were 740.00–759.99 in ICD-8 and Q0.00–Q99.9 in ICD-10.
Diagnoses of congenital dislocation of the hip and undescended
testis were excluded because of their poor validity (Larsen et al,
2003).
Record linkage
Linkage between registries was made by the civil registration
number stored in the Danish Civil Registration System together
with information on vital status, emigration, address, and nuclear
family members’ civil registration number since 1968 (Frank,
2000).
Data analysis
We classified the births of women with breast cancer according to
time of cancer diagnosis in relation to pregnancy. Group 1
included the first birth after breast cancer delivered by women who
were diagnosed at any time before pregnancy. Group 2 included
the births delivered by women with a diagnosis of breast cancer
during their pregnancy (i.e., diagnosed between the first day in the
last menstruation until the date of birth). Group 3 included births
delivered by women who were diagnosed with breast cancer after
delivery (i.e., diagnosed between the day after the date of birth
until 2 years later). If a woman gave birth more than once in this
2-year period, only the last birth before the cancer diagnosis was
included. We computed the difference between the male propor-
tion of newborns of women with breast cancer and that of
newborns of matched comparison mothers with 95% confidence
intervals (95% CI) for these differences. We estimated the
prevalence ratios (PR) using prevalence odds ratios and 95% CI
for preterm birth, low birth weight at term, stillbirth, and
congenital abnormalities by logistic regression modelling. Stillborn
children were excluded from the analyses of preterm birth, low
birth weight at term, and congenital abnormalities. We adjusted
for maternal age, parity, and calendar period of the birth. PRs for
congenital abnormalities were additionally adjusted for gestational
age. For births in Groups 1 and 3, we repeated the analyses in
strata of boys and girls to examine if sex of the child modified the
PR estimates. For births in Group 1, we evaluated whether
treatment of the mother modified the PR estimates by repeating
the analyses in strata of births of women treated with surgery alone
and births of women who received other treatment (i.e., radio-
therapy, chemotherapy, or endocrine therapy).
We used multivariate regression analysis to estimate differences
in mean birth weight adjusted for maternal age, parity, gestational
age, and calendar period of the birth. Stillborn children were
excluded from this analysis.
All analyses used SAS software, version 8.2.
The study was approved by the Danish Data Protection Agency
(record no. 2003-41-2833).
RESULTS
Descriptive data on Groups 1, 2 and 3 and their matched
comparison births are shown in Table 1. Of the 695 single births
delivered by women with BC, 216 occurred in Group 1, 37 occurred
in Group 2, and 442 occurred in Group 3. For Group 1, the median
number of days from the time of diagnosis until pregnancy (i.e.,
the first day in the last menstruation) was 753 days (range: 3–5965
days). Of the 37 births in Group 2, one woman was diagnosed
in the first trimester, five in the second, and 31 women were
diagnosed in the third.
For births delivered by women in Group 3, the median number
of days from date of the birth until date of cancer diagnosis was
417 days (range: 1–729 days).
We evaluated the proportion of male newborns of women with
breast cancer compared with that of newborns of unaffected
mothers (50 vs 52%, difference¼ 2.2%, (95% CI¼ 8.9; 4.5) for
Group 1, 49 vs 52%, difference¼ 3.4%, (95% CI¼ 20; 13) for
Group 2, and 53 vs 51%, difference¼2.5%, (95% CI¼ 2.2; 7.2)
for Group 3).
Table 2 shows the PRs for preterm birth, low birth weight at term,
stillbirth and congenital abnormalities for newborns in Groups 1–3.
There was no stillborn child among the births delivered by mothers
with breast cancer. For births in Group 1, we found no increased
odds of low birth weight at term or congenital abnormalities and no
substantial increased odds of preterm birth. For births in Group 2,
the odds of preterm birth increased by eight-fold (PR¼8.1, 95%
CI¼3.8–17). However, 10 of the 12 preterm deliveries among the
women with breast cancer were elective preterm deliveries. As a
result of the small number of outcome events, effect estimates for
Group 2 were imprecise. For Group 3 the PR of preterm birth was
1.4 (95% CI¼1.0–2.0). For low birth weight at term the PR was
1.4 (95% CI¼0.7–2.8). There was no increased prevalence of
congenital abnormalities. We found no clusters of congenital
abnormalities in any specific organ system and there was only
one case with a chromosomal abnormality (data not shown).
Stratification according to sex of the offspring in Groups 1 and 3 did
not change the overall effect estimates substantially (data not
shown), except for low birth weight at term in Group 3, in which
boys had almost three-fold increased odds (PR¼2.9; 95% CI: 1.3–
6.3), and girls had decreased odds (PR¼ 0.3; 95% CI: 0.03–2.0). For
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(surgery alone or other treatment) did not change the overall results
(data not shown).
Table 3 shows the adjusted mean differences in birth weight
between babies born to women with breast cancer and babies
born to comparison mothers. Newborns of women in Groups 1
and 3 had nearly the same mean birth weights as newborns
of comparison mothers, whereas newborns of women in Group 2
had a mean birth weight 240g (95% CI¼ 404;  76) less than
newborns of comparison mothers.
DISCUSSION
We examined the association between maternal breast cancer and
adverse birth outcome in a nationwide cohort and found little
difference in the occurrence of preterm birth, low birth weight
at term, stillbirth, or congenital abnormalities, compared with the
comparison cohort, among newborns of women who were
diagnosed with breast cancer before pregnancy.
The eight-fold increased odds of preterm birth for newborns
of women who were diagnosed with breast cancer during their
Table 1 Characteristics of births of women with breast cancer and of the comparison cohort
Births in
group 1
(N¼216)
Births in comparison
cohort (N¼10453)
Births in
group 2
(N¼37)
Births in comparison
cohort (N¼1795)
Births in
group 3
(N¼442)
Births in
comparison cohort
(N¼21195)
Maternal age at delivery, number (%)
o25 years 5 (2.3) 2441 (23.4) 1 (2.7) 419 (23) 18 (4.1) 5517 (26.0)
25–29 years 29 (13) 4054 (38.8) 8 (22) 693 (39) 104 (24) 8256 (39.0)
30–34 years 76 (35) 2853 (27.3) 13 (35) 486 (27) 184 (42) 5383 (25.4)
X35 years 106 (49) 1105 (10.6) 15 (41) 197 (11) 136 (31) 2039 (9.6)
Data missing 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0)
Age at delivery (years)
Mean (7s.d.) 34.4 (74.8) 28.2 (74.9) 33.3 (74.8) 28.3 (75.0) 32.2 (74.4) 27.8 (74.9)
Min/max 21–46 15–50 24–44 15–43 20–44 14–47
Parity, number (%)
1 92 (43) 4778 (45.8) 11 (30) 849 (47) 116 (26) 9514 (44.9)
X2 124 (57) 5665 (54.2) 26 (70) 946 (53) 326 (74) 11665 (55.1)
Data missing 0 (0.0) 10 (o0.1) 0 (0.0) 0 (0.0) 0 (0.0) 16 (o0.1)
Offspring (sex), number (%)
Male 108 (50) 5454 (52.2) 18 (49) 934 (52) 236 (53) 10782 (50.9)
Female 108 (50) 4989 (47.8) 19 (51) 861 (48) 206 (47) 10397 (49.1)
Data missing 0 (0.0) 10 (o0.1) 0 (0.0) 0 (0.0) 0 (0.0) 16 (o0.1)
Gestational age (weeks)
a
Mean (7s.d.) 39.2 (72.4) 39.6 (71.8) 37.2 (73.8) 39.5 (71.9) 39.3 (72.0) 39.6 (71.9)
Min/max 25–43 20–44 24–42 26–43 25–43 23–44
aStillborn babies were excluded from the analyses of mean gestational age. Group 1: Births of women diagnosed with breast cancer before pregnancy. Group 2: Births of women
diagnosed with breast cancer during pregnancy. Group 3: Births of women diagnosed with breast cancer from the day after giving birth and until 2 years later.
Table 2 Crude and adjusted prevalence odds ratios of birth outcome in women with breast cancer
Breast cancer cohort
outcome/total (%)
Comparison cohort
outcome/total (%)
Crude prevalence odds
ratio (95 % ci)
Adjusted prevalence
odds ratio
a (95 % CI)
Births in group 1 (N¼216) (N¼10453)
Preterm birth
b 14/216 (6.5) 507/10414 (4.9) 1.4 (0.8–2.3) 1.3 (0.7–2.2)
Low birth weight
b 3/202 (1.5) 137/9885 (1.4) 1.1 (0.3–3.4) 1.2 (0.4–3.8)
Stillbirth 0/216 (0.0) 39/10453 (0.4) — —
Abnormalities
b,c 7/203 (3.4) 369/9775 (3.8) 0.9 (0.4–1.9) 0.9 (0.4–1.9)
Births in group 2 (N¼37) (N¼1795)
Pretem birth
b 12/37 (32) 102/1785 (5.7) 7.9 (3.9–16) 8.1 (3.8–17)
Low birth weight
b 1/25 (4.0) 19/1679 (1.1) 3.6 (0.5–28) 5.3 (0.6–51)
Stillbirth 0/37 (0.0) 10/1795 (0.6) — —
Abnormalities
b,c 1/35 (2.9) 53/1685 (3.1) 0.9 (0.1–6.7) 0.5 (0.1- 3.6)
Births in group 3 (N¼442) (N¼21195)
Pretem birth
b 33/442 (7.5) 1143/21120 (5.4) 1.4 (1.0–2.0) 1.4 (1.0–2.0)
Low birth weight
b 9/408 (2.2) 329/19917 (1.7) 1.3 (0.7–2.6) 1.4 (0.7–2.8)
Stillbirth 0/442 (0.0) 75/21195 (0.4) — —
Abnormalities
b,c 16/389 (4.1) 685/18519 (3.7) 1.1 (0.7–1.9) 1.1 (0.6–1.8)
Group 1: Birth outcome in women diagnosed with breast cancer before pregnancy. Group 2: Birth outcome in women diagnosed with breast cancer during pregnancy. Group 3:
Birth outcome in women diagnosed with breast cancer from the day after giving birth and until 2 years post partum.
aPrevalence odds ratios for preterm birth and low birth
weight at term were adjusted for maternal age (o25 year, 25–29 year, 30–34 year and X35 year), parity (1, 2+) and calendar period of birth (73–86, 87–94, 95–02).
Prevalence odds ratios for congenital abnormalities were additionally adjusted for gestational age (20–33 week, 34–36 week and X37 week).
bStillborn babies were excluded
from the analyses of preterm birth, low birth weight at term and congenital abnormalities.
cData on congenital abnormalities included births from 1977 to 2002.
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probably to allow an earlier start of cancer therapy. After
adjustment for gestational age, there was a 240g reduction in
mean birth weight for newborns in this group. The association
with preterm birth in Group 3 may be explained by suboptimal
intrauterine conditions caused by a preclinical cancer. In this
group, only boys had increased odds of low birth weight at term,
suggesting that male foetuses are more vulnerable than female.
Our data are derived from a uniformly organized health care
system with complete cancer and birth registration. Some selection
problems are possible, however. If women with breast cancer had
more miscarriages or induced abortions caused by foetal
abnormalities than comparison mothers, this phenomenon could
explain why we found no increased risk of congenital abnormal-
ities. It has been suggested that exposure to severe periconcep-
tional life events might reduce the male proportion of offspring,
partly because of differential abortion of male embryos (Hansen
et al, 1999). Thus, a lower proportion of males for offspring of
the patients could be an indicator of miscarriages. Another study
has indicated an increased risk of miscarriage among women with
breast cancer (Velentgas et al, 1999). Our data, however, did not
show any important difference in male proportions between the
offspring of breast cancer women and offspring of comparison
mothers. It has been reported that women with high socio-
economic status have a higher incidence of breast cancer (Danø
et al, 2004), while low socioeconomic status has been associated
with adverse birth outcome (Luo et al, 2004). We were unable to
adjust for socioeconomic status and therefore we may have
underestimated the effect of the disease.
A recent study found that treatment data recorded in the Cancer
Register are of varying quality (Jensen et al, 2002). However, breast
cancer treatment with surgery alone was correctly registered for
95.4% (Jensen et al, 2002). Coding mistakes are infrequent in the
Birth Registry, but data have some misclassifications of gestational
age (Kristensen et al, 1996). Our data did not suggest any
differential misclassification of preterm birth between women with
breast cancer and comparison mothers.
Hospital discharge data are not always coded correctly (Larsen
et al, 2003), but Danish data on congenital abnormalities are of
high quality compared with other countries, with 80–85% coded
correctly (Larsen et al, 2003). We did not find any clusters of
congenital abnormalities in any specific organ system.
Our finding of an increased risk of giving birth preterm
for women who were diagnosed with breast cancer during or
shortly after pregnancy corroborates the results of two earlier
studies (Zemlickis et al, 1992; Smith et al, 2001). In a hospital-
based study, Smith et al (2001) identified 423 cases of breast cancer
diagnosed from 9 months preceding delivery until 12 months
after delivery over a period of 6 years in California. They
reported an odds ratio of 2.2 (95% CI¼1.7–2.8) for prematurity,
and an odds ratio of 2.0 (95% CI¼1.0–4.1) for very low birth
weight. They adjusted only for maternal age. A hospital-based
historical cohort study from 1992 of 118 women, who were
pregnant within 9 months before or 3 months after their first
treatment for breast cancer, reported a lower mean birth weight
after adjustment for gestational age and a higher proportion of
preterm births among offspring of women with breast cancer
compared with controls (Zemlickis et al, 1992). In these studies,
however, the authors did not distinguish between birth outcome of
women diagnosed with breast cancer during their pregnancy and
women diagnosed shortly after pregnancy. We found a lower mean
birth weight limited to newborns of women diagnosed during their
pregnancy.
In conclusion, this is the first population-based cohort study
of birth outcome in women diagnosed with breast cancer before
pregnancy, and the largest cohort study to date of birth outcome
in women diagnosed with breast cancer during or shortly after
pregnancy. Overall, our results are reassuring regarding the risks
of adverse birth outcome for women with breast cancer.
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